Description:AVL-292, also known as a selective inhibitor of Bruton's tyrosine kinase (BTK), is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications in treating various hematological malignancies and autoimmune diseases. As a BTK inhibitor, AVL-292 works by disrupting the signaling pathways that are crucial for the survival and proliferation of B cells, which are often implicated in these conditions. The compound is characterized by its ability to selectively bind to the BTK enzyme, thereby inhibiting its activity without significantly affecting other kinases, which helps to minimize off-target effects. AVL-292 has undergone various preclinical and clinical studies to evaluate its efficacy and safety profile. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its therapeutic potential. Overall, AVL-292 represents a promising avenue for targeted therapy in diseases driven by aberrant B cell signaling.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide](https://static.cymitquimica.com/products/IN/thumb/DA003A6K.jpg)
